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Since their introduction in 1988, PPIs have 
revolutionized the management of reflux dis­
ease and peptic ulcer disease with substantial 
reduction in the morbidity and mortality 
associated with these conditions. As such, 
PPIs are now among the most commonly 
prescribed medications worldwide. However, 
perhaps because of their laudable benefits, 
PPIs have also been prescribed for a myriad 
of gastrointestinal complaints or suspected 
reflux syndromes without clear need or bene­
fit, resulting in substantial overutilization1. 
The over­the­counter availability of PPIs has 
probably accelerated this trend. To compli­
cate matters, several epidemiological stud­
ies in recent years have identified possible 
adverse outcomes associated with long­term 
PPI use. Each of these publications has been 
widely reported in the media, prompting both 
physicians and patients to question the safety 
of long­term PPI use. The recent article by 
Lazarus et al.1 published in JAMA Internal 
Medicine is part of this growing literature 
reporting potential risks of PPIs use.
The study by Lazarus et al.1aimed to quan­
tify the association between PPIuse and inci­
dent chronic kidney disease (CKD) in two 
population­based cohorts,the Atherosclerosis 
Risk in Communities (ARIC) study and the 
Geisinger Health System replication cohort 
in the USA. H2 receptor antagonist use was 
considered a negative control and active com­
parator. Using statistical modelling tools and 
study giventhat it was an uncontrolled obser­
vational  epidemiological study reporting a 
HR of <1.5?
Observational studies often demonstrate 
weak associations, defined by epidemio logists 
as a relative risk or odds ratio between 1 and 
4 but, by their nature, they cannot assess the 
validity of those observations2. Although statis­
tically significant and quite ‘precise’, as reflected 
by the small confidence intervals and P values 
<0.05, precision does not equate with validity. 
In other words, they can be precisely wrong2. 
There are just too many potential confounding 
variables and sources of bias in observational 
studies. Increasing the sample size increases 
the precision of the estimate, but does not 
circumvent the problem of selection bias and 
confounding variables. Furthermore, simply 
identifying potential confounding variables as 
the authors have endeavoured to do does not 
eliminate them; beyond being unrecognized, 
confounding variables can be unmeasured or 
poorly measured, causing bias. In reviewing 
the data presented, one has to agree that there 
was an association between CKD and incident 
PPI use in these cohorts. However, this associ­
ation does not establish causality. Large sample 
sizes, small P values and narrow confidence 
intervals in the context of a small effect size 
do not prove the validity of those small effects. 
Furthermore, the validity of any small effects in 
observational studies such as this one is doubt­
ful, with numerous epidemiologists suggesting 
that effect sizes <3 are usually wrong and more 
appropriately classified as ‘noise, not signal’ 
(REF. 2). One has to accept the inherent selec­
tion, surveillance and confounding biases 
associated with large observational studies 
controlling for several potential confound­
ing variables, the authors reported that PPI 
use was associated with the development 
of incident CKD with an adjusted hazard 
ratio (HR) of 1.5 (95% CI 1.14–1.96) in the 
ARIC studyand 1.24 (95% CI 1.20–1.28) 
in the Geisinger cohort. In the Geisinger 
cohort, twice­daily PPI dosing was associ­
ated with a higher risk (adjusted HR 1.46; 
95% CI 1.28–1.67) than once­daily dosing 
(adjusted HR 1.15; 95% CI 1.09–1.21). From 
this finding, they concluded that PPI use is 
associated with an increased risk of incident 
CKD. Within days, The New York Times ran 
a health column entitled, “Study Finds 
Growing Reason to Be Wary of Some Reflux 
Drugs”. But was this research really a positive 
 T H E R A P Y
Risks associated with chronic 
PPI use — signal or noise?
Leila Kia and Peter J. Kahrilas
Chronic kidney disease has joined the growing list (pneumonia, myocardial 
infarction, hip fracture, Clostridium difficile infections, acute interstitial 
nephritis, hypomagnesaemia) of putative risks associated with chronic PPI 
use based on results from an observational epidemiological study. However, 
the low hazard ratio (<1.5) makes it doubtful that this association is a 
causal relationship.
Refers to Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176,  
238–246 (2016)
Table 1 | Reported associations with PPI use and adverse events
Adverse event Odds or hazard ratio 95% CI
Hip fracture with PPI use >1 year4 OR 1.44 1.30–1.59
Hip fracture with long-term PPI use OR 2.65 1.80–3.90
Community-acquired pneumonia5 OR 1.49 1.16–1.92
Clostridium difficile infection6 OR 2.10 1.20–3.50
Acute interstitial nephritis7 OR 5.16 2.21–12.05
Acute kidney injury in patients >18 years8 OR 1.72 1.27–2.32
Hypomagnesaemia3 OR 1.78 1.01–2.92
Myocardial infarction9 HR 1.16 1.09–1.24
Dementia10 HR 1.44 1.36–1.52
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of this kind, any of which can easily account 
for the reported outcome. Although Lazarus 
et al.1 used elegant statistical modelling and 
present statistically significant findings, the 
fact remains that the effect size was very small, 
much less than the threshold value of 2–3 usu­
ally deemed necessary to make the finding 
worthy of consideration for possible causality2.
Regardless of these arguments, the alarm 
has been sounded with the new findings 
reported on network TV news as a “PPI risk” 
and patients already clamouring for advice. So, 
like it or not, CKD has been added to the list 
of potential adverse events associated with PPI 
use. How do Lazarus et al.1 findings compare 
with previous reports of PPI risks? Although 
the information in TABLE 1 is not comprehen­
sive, it includes the major relevant studies. In 
reviewing these data, the majority of effect 
sizes are small or very small, similar to values 
reported by the Lazarus et al.1 study. Acute 
interstitial nephritis is the exception with an 
odds ratio >5, suggesting probable signal as 
opposed to noise. As for the remainder, it is 
unclear whether or not any of them have clin­
ical relevance. They might, but this evidence 
does not warrant changing practice patterns, 
particularly when a PPI is appropriately clin­
ically indicated. A case in point would be 
that of hypomagnesaemia. Although initially 
reported as a potential PPI risk with a (low) 
HR of 1.78, a critical re­examination of pos­
sible cases of PPI­related hypomagnesaemia 
in a large health maintenance organization 
database published in 2016 concluded: “in the 
absence of known precipitating factors, chronic 
PPI use does not appear to be  associated with 
hypomagnesemia” (REF. 3).
So faced with the patient or physician con­
templating discontinuation of PPI therapy 
due to concern over long­term risks, how to 
respond? First, the indication for PPI use 
should be reviewed. If the PPI was initiated 
for a dubious syndrome for which it proved to 
be ineffective, it should be discontinued. That 
is an easy one. No matter how miniscule the 
risk, there is no benefit. Secondly, if the PPI was 
started at a higher than standard dose, or if the 
dosage was increased without clear reason or 
clinical benefit, the dosage should be decreased 
to the standard dose. More is not necessarily 
better. In fact, higher doses are more likely to 
lead to adverse effects and events. Finally, one 
needs to have a frank discussion with patients 
and providers about the lack of meaningful 
data on PPI risk to  warrant changing practice. 
Remember, PPIs revolutionized the manage­
ment of acid­ related disorders. Yes, they have 
been severely over­used, but used appropriately 
they have proven to be extremely safe drugs 
and have helped  innumerable patients.
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